Genomics England has completed installation of an enterprise imaging system that will help to support a world-pioneering initiative for cancer research.
The programme is linking whole genome sequencing, pathology, and radiology data in what has been described as the world’s-largest multi-modal cancer research platform.
First announced in 2022 as a means to support new discoveries, Genomics England’s programme will help a wide range of researchers and scientists create a better understanding of cancer.
And it is hoped that this will lead to new treatments, as well as supporting the development of cancer-targeting AI.
Bringing data to the forefront
Genomics England has now deployed technology from medical imaging technology provider, Sectra, that will play a central role in allowing the organisation to bring together underpinning data so that researchers and developers from a wide variety of backgrounds can harness it in new ways.
In particular, the enterprise imaging system will allow Genomics England to incorporate NHS imaging data, while the Image Exchange Portal, a system used nationally by the NHS, will also allow it to transport images from participating NHS trusts.
This programme will push the boundaries of cancer research and how we work and has the potential to transform clinical trials, change who can do research and development, and lead to the creation of new targeted treatments for cancer patients
This will mean diagnostic imaging data captured in the NHS, including radiology images such as X-rays, CT, and MRI scans, and digital pathology images generated by NHS laboratories, can be linked with whole genome sequencing data from Genomics England.
To begin with 30 NHS trusts in England are providing data on solid tumours. This includes approximately 250,000 pathology images and 200,000 radiology scans for 16,000 participants.
Pushing the boundaries
Once the radiology and pathology data in the system is matched with the genomics data, multi-modal data will be used by researchers to investigate and identify markers for cancer diagnostics and treatments.
Information will be kept highly secure, with patient-identifiable data removed for researchers outside of Genomics England, who will only have access to a Genomics England ID number, the age of the participant, and the name of the NHS site at which the data was captured.
Dr Prabhu Arumugam, director of clinical data and imaging and Caldicott Guardian for Genomics England, said: “This programme will push the boundaries of cancer research and how we work and has the potential to transform clinical trials, change who can do research and development, and lead to the creation of new targeted treatments for cancer patients.
“We will be able to understand mutations and when things go wrong in DNA and, importantly, whether that transpires into what clinicians see in medical imaging.
New ways of working
“We can also expose data in new ways to AI and all of that can help to facilitate new drug discoveries and better inform which patients might benefit from particular treatments.”
He added: “Innovative working with Sectra is an important part of our initiative.
This is an inspirational initiative, that could help to change our understanding of cancers and other illnesses
“The imaging system is already a very-recognisable interface in NHS clinical settings, but we are using it in new ways.
“It will help us to harness imaging that we can then match to our genomic data, while de-identifying data to ensure confidentiality.
“The resulting multi-modal dataset will enable important research, break down traditional barriers, and support a safe and secure but accessible cloud-based research environment that means many more people than bioinformaticians can harness genomic, pathology and radiology data.”
Deployed in the Genomics England’s cloud environment, the new research platform will be easily accessible for users, through a secure, fast, and reliable interface.
Cloud deployment will also provide the flexibility to scale the initiative as more users come on board and as the programme potentially expands to support research for non-cancers in the future.
Life changing and life saving
Sectra’s enterprise imaging system is widely used in the NHS, where it supports healthcare professionals in diagnosing patient illness.
The system installation was completed in February 2023 after a contract was awarded earlier in 2022.
Jane Rendall, UK and Ireland managing director for Sectra, said: “This is an inspirational initiative, that could help to change our understanding of cancers and other illnesses.
“We have been working with the NHS for decades in delivering digital maturity to diagnostic environments including radiology and pathology and this project makes greater use of that work, with exciting possibilities for research that could be immense.
“I eagerly look forward to seeing research emerge, and from that the potential for life-changing and life-saving treatments for patients.”